- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 12: A New Precedent for Healthcare
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
Matthew D. Harman, PharmD, MPH, added that the upcoming PCSK9 for high cholesterol is highlighting the trend of the “specialization of traditional drug classes.” For instance, there are medications coming out for asthma and diabetes that are more targeted.
“[These targeted therapies] are going to cost tens of thousands of dollars and there’s most likely will be demand for that,” he said. “And how are we going to sustain that?”
Diabetes Risk Driven by Economic Disparity in Hispanic, Latino Communities
March 28th 2025Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
